Andre Habel

Title: Andre Habel: Innovator in Viral Research

Introduction

Andre Habel is a notable inventor based in Hamburg, France. He has made significant contributions to the field of viral research, particularly in the development of innovative vaccine formulations. His work focuses on the recombinant measles virus and its applications in combating viral infections.

Latest Patents

Habel holds a patent for a "Recombinant measles virus expressing chikungunya virus polypeptides and their applications." This invention relates to recombinant measles virus that expresses chikungunya virus polypeptides. It specifically concerns virus-like particles (VLP) that contain envelope and capsid proteins of the chikungunya virus on their surface. These particles are recombinant infectious particles capable of replicating in a host after administration. The invention provides various means, including nucleic acids, vectors, cells, and rescue systems, to produce these recombinant infectious particles. Additionally, it relates to the use of these particles, particularly in vaccine formulations, for the treatment or prevention of chikungunya virus infections.

Career Highlights

Throughout his career, Andre Habel has worked with prestigious organizations, including Institut Pasteur and Themis Bioscience GmbH. His research has been pivotal in advancing the understanding of viral mechanisms and developing effective therapeutic strategies.

Collaborations

Habel has collaborated with notable colleagues in the field, including Frederic Tangy and Samantha Brandler. Their combined expertise has contributed to the success of various research projects and innovations.

Conclusion

Andre Habel's work exemplifies the importance of innovation in the field of viral research. His contributions, particularly in developing recombinant viral particles for vaccine applications, highlight the potential for scientific advancements to address global health challenges.